<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2359">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432324</url>
  </required_header>
  <id_info>
    <org_study_id>GC2004</org_study_id>
    <secondary_id>2020-001696-32</secondary_id>
    <nct_id>NCT04432324</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)</brief_title>
  <official_title>A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if high dose Intravenous IVIG plus SMT can reduce&#xD;
      the proportion of participants dying or requiring intensive care unit (ICU) admission on or&#xD;
      before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical&#xD;
      ventilation on Day 29 versus SMT alone in hospitalized participants with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Dying or Requiring ICU Admission</measure>
    <time_frame>Up to Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who are Dependent on High Flow Oxygen Devices or Invasive Mechanical Ventilation</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in National Early Warning Score (NEWS)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospital Discharge</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU Stay</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Any Oxygen Use</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Value Change from Baseline in Ordinal Scale</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Time to Clinical Progression</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale</measure>
    <time_frame>Day 15 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Normalization of Temperature</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Normalization of Fever</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Intravenous Immune Globulin + Standard Medical Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the first intravenous (IV) infusion of IVIG on Day 1 up to a net dose of 2 gram per kilogram (g/kg), based upon participant's (body weight) administered in divided doses as infusions of 500 milligram per kilogram (mg/kg), based upon participant's body weight, over 4 days or 400 mg/kg, based upon participant's body weight, over 5 days. Participants will also receive all standard of care interventions while hospitalized, from Day 1 to Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive all standard of care interventions required throughout the participant's hospitalization, from Day 1 to Day 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous Immune Globulin</intervention_name>
    <description>IVIG Intravenous infusion</description>
    <arm_group_label>Intravenous Immune Globulin + Standard Medical Treatment</arm_group_label>
    <other_name>Flebogamma DIF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>SMT</description>
    <arm_group_label>Intravenous Immune Globulin + Standard Medical Treatment</arm_group_label>
    <arm_group_label>Standard Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized male or female subject ≥ 18 years of age at time of Screening who is&#xD;
             being treated for COVID-19.&#xD;
&#xD;
          2. Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by&#xD;
             qualitative Polymerase Chain Reaction (PCR) (reverse transcriptase [RT]-PCR), or other&#xD;
             commercial or public health assay (of any type) in any specimen during the current&#xD;
             hospital admission prior to randomization.&#xD;
&#xD;
          3. COVID-19 illness (symptoms) of any duration with radiographic infiltrates by imaging&#xD;
             (Chest X-Ray, Computed tomography (CT) scan, etc.).&#xD;
&#xD;
          4. PaO2/FIO2 ratio &gt; 300 to ≤ 450 mmHg (i.e., arterial oxygen in mmHg divided by fraction&#xD;
             inspired oxygen concentration [e.g., 0.21 for room air])&#xD;
&#xD;
          5. Any one of the following related to COVID-19: i. Ferritin &gt; 400 nanogram per&#xD;
             milliliter (ng/mL), ii. Lactate dehydrogenase (LDH) &gt; 300 units per liter U/L, iii.&#xD;
             D-Dimers &gt; reference range, or iv. C-reactive protein (CRP) &gt; 40 milligram per liter&#xD;
             (mg/L).&#xD;
&#xD;
          6. Subject (or a legal representative or a nearest relative or a relative by marriage, as&#xD;
             appropriate) provides oral informed consent prior to initiation of any study&#xD;
             procedures.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subject requires invasive mechanical ventilation or ICU admission.&#xD;
&#xD;
          2. Clinical evidence of any significant acute or chronic disease that, in the opinion of&#xD;
             the investigator may place the subject at undue medical risk.&#xD;
&#xD;
          3. The subject has had a known (documented) serious anaphylactic reaction to blood, any&#xD;
             blood-derived or plasma product or commercial immunoglobulin.&#xD;
&#xD;
          4. Subject has known (documented) hereditary fructose intolerance (HFI).&#xD;
&#xD;
          5. A medical condition in which the infusion of additional fluid is contraindicated.&#xD;
&#xD;
          6. Shock that is unresponsive to fluid challenge and/or multiple vasopressors and&#xD;
             accompanied by multiorgan failure considered by the Principal Investigator not able to&#xD;
             be reversed.&#xD;
&#xD;
          7. Subject with known (documented) thrombotic complications to polyclonal IVIG therapy in&#xD;
             the past.&#xD;
&#xD;
          8. Subject with current or prior (within the past 1 month) myocardial infarction, stroke,&#xD;
             deep vein thrombosis, or thromboembolic event.&#xD;
&#xD;
          9. Subject with limitations of therapeutic effort (eg, 'do not resuscitate' status).&#xD;
&#xD;
         10. Female subject who are pregnant or of child-bearing potential with a positive test for&#xD;
             pregnancy blood or urine human chorionic gonadotropin (HCG)-based assay at&#xD;
             Screening/Baseline.&#xD;
&#xD;
         11. Subject participating in another interventional clinical trial with investigational&#xD;
             medical product or device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Navarro Puerto Jordi</last_name>
    <phone>+34935712200</phone>
    <email>jordi.navarro@grifols.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elsa Mondou</last_name>
    <phone>919-316-2079</phone>
    <email>elsa.mondou@grifols.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>San Sebastián De Los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Perales, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabel Perales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Lluisa Pedro-Botet, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Lluisa Pedro-Botet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benito Almirante Gragera, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benito Almirante Gragera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Solanich Moreno, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier Solanich Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>CP 08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Domingo Pedrol, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pere Domingo Pedrol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Abad, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Abad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jéssica González Gutiérrez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jéssica González Gutiérrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Alberto Carbone Campoverde, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Alberto Carbone Campoverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicente Estrada Perez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vicente Estrada Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus Disease</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

